The factors that determine whether a given individual will develop rheumatic fever after a streptococcal pharyngitis have not been clarified. The low incidence of this disease, despite the prevalence of streptococcal respiratory infections, and the high familial incidence suggest a genetic factor. A recent study, however, shows that rheumatic fever does not follow the pattern of a simple recessive gene (1) . Rheumatic symptoms develop after mild as well as severe infections due to any one of 50 known types of Group A Streptococci. Attempts to prove that any particular cellular component or enzyme produced by these organisms is the cause of this disease have so far proved negative.
Rheumatic fever is uncommon in children less than five years of age. The mean titers of antistreptococcal antibodies in patients with acute rheumatic fever tend to be higher than in children with uncomplicated streptococcal infections (2) . These observations suggested that repeated, closely spaced attacks of streptococcal pharyngitis may be a determining factor (3) .
It is usually not possible to obtain a reliable history of remote respiratory infections. Furthermore, even if the illness is recalled, streptococcal pharyngitis usually cannot be differentiated from a sore throat of viral origin. The commonly studied antistreptococcal antibodies, such as antistreptolysin 0, are not type-specific and may show a rise in titer after infection with any one of the 50 types of Group A Streptococci. These antibodies usually appear one to two weeks after the infection and in most instances return to normal levels after two to six months.
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tococcal types under study was included in each series of tests. Since many of the patients with acute rheumatic fever were receiving penicillin therapy, 0.05 ml of penicillinase (100 U per 10 ml) was added to each tube. The prepared tubes were placed in a rotating machine driven at 6 to 8 rpm and incubated at 370 C. After 3 hours of rotation, pour plates were made with 0.1 ml from each tube and agar containing 5% sheep blood. To determine the size of the inoculum at the start of the test, additional pour plates were made with 0.1 ml of each of the original serial culture dilutions mixed with sheep blood agar. The plates were incubated overnight, and the number of colonies which grew out from the inoculum was compared with colony count or estimate1 from the control and test mixtures. The method was considered satisfactory if 1) the inoculum was small (from 100 to 250 colonies in the 10' dilution and from 1 to 15 colonies in the 1: 128 dilution) and 2) a vigorous growth occurred in the normal control serum. The unknown serum was considered positive for antibody against the homologous type if there was a significant suppression of growth in each culture dilution mixed with test serum as compared to the control serum and the result could be reproduced. The protocols of two representative test series are shown in Tables III and IV In the left column of 
DISCUSSION
The results of this study suggest that the incidence of past streptococcal disease, exclusive of the infection which triggered the acute attack, is probably no greater in the rheumatic subject that in the nonrheumatic individual. By utilizing the bactericidal test, type-specific antibodies were detected against one or more of 13 prevalent types of Group A Streptococci in 65% of patients with acute rheumatic fever and in 52% of control children. The difference is not statistically significant. The similarity between the groups is more striking when children with antibodies against more than one type are considered separately: 28%o of the rheumatic group and 25%o of the control series had multiple type-specific antibodies.
The findings obtained in this study provide no evidence to support the concept that susceptibility to rheumatic fever is related to an inordinately high incidence of prior streptococcal infections. There are no data available on the incidence of clinically observed streptococcal infection in patients who subsequently develop their initial attack of rheumatic fever. Taranta (8) documented streptococcal illness in a group of individuals with a known past history of rheumatic fever, and in this highly susceptible group, it is significant that no correlation was found between the recurrence rate and the number of streptococcal infections prior to the one which initiated the recurrent attack. It should be pointed out, however, that although the type-specific antibody pattern reflects the incidence of past streptococcal disease, it is not possible to know when and in what sequence the remote infections occurred. Therefore, the data do not exclude the possibility that the past infections may have been more closely spaced in the rheumatic individuals. Studies by Winblad, Malmros, and Wilander (9) suggest that rheumatic fever is more likely to occur following cross-infection with a second type of Streptococcus. On the other hand, Stetson (10) found no relationship between closely spaced infections and the attack rate of rheumatic fever.
Rantz, Maroney, and Di Capro ( 11 ) have shown that the magnitude of the antistreptolysin 0 response to streptococcal infections increases from infancy through childhood and this change is probably a function of repeated infections with these organisms. It has been inferred from these studies that rheumatic fever is infrequent in preschool children because the response to antigenic stimuli is less marked in young than in older individuals. If this theory is correct, then it would seem reasonable to expect that when a young child develops rheumatic fever he probably has had greater exposure to streptococcal disease than other children in a similar age group. The data obtained in this study do not support this hypothesis. Although there were only nine patients with acute rheumatic fever in this study who were four to six years of (15) have shown that type-specific antibodies may disappear from the blood within two to three years in 50% of the patients and that the titer can be recalled by small doses of cell wall vaccines of homologous types. Also, penicillin therapy for past infections may have suppressed anti-M antibody in some children included in the study. It is not possible to assess the extent that the above factors may have modified the antibody patterns observed, but there is no reason to suspect that these factors did not apply equally to both groups of children.
The purpose of this investigation was to determine the remote streptococcal history of patients and to exclude insofar as possible the effect of recent infections on the type-specific antibody pattern. Since anti-M antibodies form slowly and since serum specimens were obtained early in the attack of rheumatic fever in all but a few patients, it is likely that the type-specific antibody patterns observed did not reflect the recent streptococcal illness. It is possible, however, that among the small number of rheumatic subjects in whom specimens were obtained three weeks after the onset of the attack, measurable type-specific antibody from a recent infection may have occurred. This might account for the slightly higher incidence of typespecific antibodies observed in the rheumatic group.
The two groups of children varied markedly in respect to evidence of recent streptococcal infection. Thirty of 32 patients in the rheumatic group had an antistreptolysin 0 titer above 250 U, while five children in the control group had titers above this level. These findings are in keeping with the established fact that a preceding streptococcal infection can be demonstrated in almost every case of rheumatic fever, and it should not be inferred from the data obtained on type-specific antibodies that any doubt is cast on this wellknown relationship.
SUMMARY AND CONCLUSIONS 1. Type-specific antibodies against 13 prevalent types of Group A Streptococci were determined by bactericidal tests on the sera of a group of patients with acute rheumatic fever and of a group of suitable control children.
2. Type-specific antibodies against one or more types were demonstrated in 65% of patients with acute rheumatic fever and in 52% of control children. The rheumatic patients did not have antibodies against a greater number of types than the control children.
3. Antibodies against more than one type occurred more commonly among the older children of both groups. 4 . No correlation could be demonstrated between the magnitude of the antistreptolysin 0 titer and the type-specific antibody pattern in patients with acute rheumatic fever.
5. Since the presence of type-specific antibody is evidence of a past infection with an homologous type, the data obtained suggest that the rheumatic host has not had more frequent streptococcal infections prior to the first attack than the nonrheumatic individual.
